首頁 > 市場調查報告書 > 製藥

眼科藥物

乾眼症市場規模、佔有率和成長分析（按產品、劑型、通路和地區分類）－2025-2032年產業預測

市場調查報告書

商品編碼

1865244

乾眼症市場規模、佔有率和成長分析（按產品、劑型、通路和地區分類）－2025-2032年產業預測

Dry Eye Syndrome Market Size, Share, and Growth Analysis, By Product (Over the Counter Artificial Tears & Lubricants, Prescription Drugs), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月07日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2023 年，全球乾眼症市場規模將達到 77 億美元，到 2024 年將成長至 83.1 億美元，到 2032 年將成長至 152.6 億美元，預測期（2025-2032 年）的複合年成長率為 7.9%。

全球乾眼症 (DES) 市場分析顯示，治療方式正顯著從非處方藥轉向針對發炎機制的處方藥。創新處方藥技術正在湧現，專注於緩解疾病療法，以解決瞼板腺功能障礙、眼表發炎和淚膜不穩定等問題。乾眼症盛行率的不斷上升，尤其是在老年人和伴隨其他疾病的人群中，進一步推動了這一成長。 60 歲及以上人口的快速成長加劇了全球乾眼症發病率的上升。目前，數百萬人患有嚴重的乾眼症，歐洲和東亞等地區的病例呈現上升趨勢。這個不斷變化的市場凸顯了對有效且有針對性的治療方案的需求。

推動全球乾眼症治療市場發展的因素

全球乾眼症市場受到人口老化和乾眼症盛行率上升的顯著影響。隨著越來越多的老年人需要持續的眼部護理，處方箋和非處方藥的需求也相應成長。此外，螢幕使用時間的激增可能會即時推動潤滑劑銷售的成長，並持續增加對治療性介入的需求。北美目前是領先的市場，展現出強勁的收入成長潛力。因此，該市場為創新治療方法和診斷服務提供了廣闊的發展空間，確保了該領域持續的機會。

限制全球乾眼症治療市場的因素

儘管乾眼症 (DED) 的盛行率很高，但許多患者仍未被診斷和治療。在許多情況下，患者放棄就醫，選擇自行服用非處方藥。這種趨勢限制了用於有效控制和治療疾病的藥物的收入潛力，也使得患者難以過渡到處方藥治療。確診患者中服用處方藥的比例相對較低，阻礙了更先進、更昂貴的治療方案的整體成長潛力。因此，這些因素是全球乾眼症市場的重要阻礙因素因素。

全球乾眼症市場趨勢

全球乾眼症市場正經歷顯著的轉變，治療重點從單純緩解症狀轉向針對潛在疾病過程的處方藥物和療法。臨床醫生越來越傾向於採用專注於改善淚膜穩定性和抑制發炎路徑的創新治療方法。胜肽類、神經興奮劑和緩釋緩釋性等新型藥物的出現，以及突破性臨床試驗的發展，都推動了這項轉變。此外，專科診所和個人化處方箋的興起正在重塑治療模式，將重點轉向長期管理策略，預計將顯著推動市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2024 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024 年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2022-2024年營收年比比較

主要企業簡介

AbbVie Inc.（United States）
Bausch+Lomb（Canada）
Novartis AG（Switzerland）
Johnson & Johnson Services, Inc.（United States）
Santen Pharmaceutical Co., Ltd.（Japan）
Alcon Inc.（Switzerland）
Sun Pharmaceutical Industries Ltd.（India）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Viatris Inc.（United States）
Kala Pharmaceuticals, Inc.（United States）
Novaliq GmbH（Germany）
AFT Pharmaceuticals（New Zealand）
Aldeyra Therapeutics（United States）
OASIS Medical（United States）
Akorn Operating Company LLC（United States）
Nicox SA（France）
Ocular Therapeutix, Inc.（United States）
Mitotech SA（Luxembourg）
Tarsus Pharmaceuticals, Inc.（United States）
Stuart Therapeutics（United States）

結論與建議

簡介目錄

Product Code: SQMIG35G2356

Global Dry Eye Syndrome Market size was valued at USD 7.7 billion in 2023 and is poised to grow from USD 8.31 billion in 2024 to USD 15.26 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

Market insights for the global dry eye syndrome (DES) segment indicate a notable shift towards prescription therapies targeting inflammatory mechanisms, moving away from over-the-counter lubricants. Innovative prescription drug technologies are emerging, focusing on disease-modifying treatments that address concerns like meibomian gland dysfunction, ocular surface inflammation, and tear-film instability. This growth is further fueled by the increasing prevalence of dry eye disease, particularly among the aging population and those with related health conditions. The demographic of individuals over 60 is expanding rapidly, contributing to the rising incidence globally. Currently, millions are affected by significant dry eye, with cases rising in regions such as Europe and East Asia, highlighting the necessity for effective, targeted treatment options in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Eye Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Eye Syndrome Market Segments Analysis

Global Dry Eye Syndrome Market is segmented by Product, Dosage Form, Distribution Channel and region. Based on Product, the market is segmented into Over the Counter (OTC) Artificial Tears & Lubricants, Prescription Drugs, Punctual Plugs, Nutraceuticals & Omega-3 Supplements and Autologous Serum & Blood-Derived Tear Substitutes. Based on Dosage Form, the market is segmented into Eye Drops and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Independent Pharmacies & Drug Stores and Online Pharmacies & E-Commerce Portals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is significantly influenced by the growing aging population alongside an increase in the prevalence of dry eye conditions. As more elderly individuals require ongoing eye care, there is a corresponding demand for both prescription and over-the-counter treatments. Additionally, the surge in screen time among individuals contributes to an immediate uptick in lubricant sales and may create a sustained need for therapeutic interventions. North America currently stands out as a leading market, indicating a robust potential for revenue growth. Consequently, the landscape is ripe for innovative treatments and diagnostic services, ensuring ongoing opportunities in this sector.

Restraints in the Global Dry Eye Syndrome Market

Despite the widespread occurrence of dry eye disease (DED), a significant number of patients remain undiagnosed and untreated. Often, individuals choose not to consult a healthcare professional, opting instead for self-treatment using over-the-counter eye drops. This behavior limits the revenue potential for medications specifically developed to manage or progress the condition effectively, while also complicating the transition to prescription treatments. The relatively low percentage of diagnosed patients who receive prescription medication impedes the overall growth potential of utilizing more advanced and costly therapeutic options. Consequently, these factors represent considerable constraints within the global dry eye syndrome market.

Market Trends of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is experiencing a significant trend towards prescription medications and treatments that target the underlying disease process rather than merely alleviating symptoms. Clinicians are increasingly shifting their preference towards innovative therapies that focus on enhancing tear film stability and addressing inflammatory pathways. This evolution is supported by the emergence of new pharmacological options, including peptides, neurostimulatives, and sustained-release formulations, alongside the initiation of groundbreaking clinical trials. Furthermore, the rise of specialty clinics and tailored formularies is redefining treatment paradigms, positioning the market for substantial growth as the focus transitions to long-term management strategies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Dry Eye Syndrome Market Size by Product & CAGR (2025-2032)

Market Overview
Over the Counter (OTC) Artificial Tears & Lubricants
Prescription Drugs
Punctual Plugs
Nutraceuticals & Omega-3 Supplements
Autologous Serum & Blood-Derived Tear Substitutes

Global Dry Eye Syndrome Market Size by Dosage Form & CAGR (2025-2032)

Market Overview
Eye Drops
Ointments & Gels

Global Dry Eye Syndrome Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Independent Pharmacies & Drug Stores
Online Pharmacies & E-Commerce Portals

Global Dry Eye Syndrome Market Size & CAGR (2025-2032)

North America (Product, Dosage Form, Distribution Channel)
- US
- Canada
Europe (Product, Dosage Form, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Dosage Form, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Dosage Form, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Dosage Form, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch + Lomb (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kala Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novaliq GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AFT Pharmaceuticals (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aldeyra Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OASIS Medical (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akorn Operating Company LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nicox S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitotech S.A. (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsus Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stuart Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments